Cargando…

Smoking Affects the Patterns of Metabolic Disorders and Metabolic Syndrome in Patients With First-Episode Drug-Naive Schizophrenia: A Large Sample Study Based on the Chinese Han Population

OBJECTIVE: Although metabolic disorders and smoking are common in schizophrenia, few studies have investigated the effects of smoking on metabolic disorders or metabolic syndrome (MetS) in schizophrenia patients, especially in first-episode drug-naïve (FEDN) patients. We sought to investigate the di...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zezhi, Wang, Shuning, Chen, Yuping, Wu, Xi, Gu, Yinjun, Lang, Xiaoe, Wu, Fengchun, Zhang, Xiang Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538889/
https://www.ncbi.nlm.nih.gov/pubmed/34153098
http://dx.doi.org/10.1093/ijnp/pyab038
_version_ 1784588614472040448
author Li, Zezhi
Wang, Shuning
Chen, Yuping
Wu, Xi
Gu, Yinjun
Lang, Xiaoe
Wu, Fengchun
Zhang, Xiang Yang
author_facet Li, Zezhi
Wang, Shuning
Chen, Yuping
Wu, Xi
Gu, Yinjun
Lang, Xiaoe
Wu, Fengchun
Zhang, Xiang Yang
author_sort Li, Zezhi
collection PubMed
description OBJECTIVE: Although metabolic disorders and smoking are common in schizophrenia, few studies have investigated the effects of smoking on metabolic disorders or metabolic syndrome (MetS) in schizophrenia patients, especially in first-episode drug-naïve (FEDN) patients. We sought to investigate the differences in metabolic disorders and MetS between smoking and nonsmoking FEDN schizophrenia patients. METHODS: A total of 428 FEDN schizophrenia patients and 435 controls were recruited. Blood pressure, waist circumference, body mass index (BMI), lipid profiles, and glucose metabolism were measured. The psychopathology was evaluated by Positive and Negative Syndrome Scale. RESULTS: FEDN schizophrenia patients had a higher smoking rate than controls (23.8% vs 14.0%, P < .001). After adjusting for confounding variables, the prevalence of MetS, overweight, hypertension, hypertriglyceridemia, elevated insulin, and insulin resistance in smoking patients was higher than those in nonsmoking patients, while overweight and hypertension were higher in the smoking controls than in nonsmoking controls (all P < .05). In smoking patients, triglyceridemia, high-density lipoprotein cholesterol, and fasting blood glucose were the main contributing components to MetS, while in nonsmoking patients, waist circumference, systolic blood pressure, triglyceridemia, high-density lipoprotein cholesterol, and fasting blood glucose were the main contributing components to MetS. In smoking patients, BMI and homeostatic model assessment for insulin resistance were associated factors of MetS (both P < .05). In nonsmoking patients, sex, BMI, insulin, and homeostatic model assessment for insulin resistance were associated factors of MetS (all P < .05). CONCLUSIONS: Our study indicates that smoking schizophrenia patients have a higher prevalence of MetS and metabolic disorders than nonsmoking patients. Moreover, smoking and nonsmoking patients have different contributing components and associated factors for MetS.
format Online
Article
Text
id pubmed-8538889
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-85388892021-10-25 Smoking Affects the Patterns of Metabolic Disorders and Metabolic Syndrome in Patients With First-Episode Drug-Naive Schizophrenia: A Large Sample Study Based on the Chinese Han Population Li, Zezhi Wang, Shuning Chen, Yuping Wu, Xi Gu, Yinjun Lang, Xiaoe Wu, Fengchun Zhang, Xiang Yang Int J Neuropsychopharmacol Regular Research Articles OBJECTIVE: Although metabolic disorders and smoking are common in schizophrenia, few studies have investigated the effects of smoking on metabolic disorders or metabolic syndrome (MetS) in schizophrenia patients, especially in first-episode drug-naïve (FEDN) patients. We sought to investigate the differences in metabolic disorders and MetS between smoking and nonsmoking FEDN schizophrenia patients. METHODS: A total of 428 FEDN schizophrenia patients and 435 controls were recruited. Blood pressure, waist circumference, body mass index (BMI), lipid profiles, and glucose metabolism were measured. The psychopathology was evaluated by Positive and Negative Syndrome Scale. RESULTS: FEDN schizophrenia patients had a higher smoking rate than controls (23.8% vs 14.0%, P < .001). After adjusting for confounding variables, the prevalence of MetS, overweight, hypertension, hypertriglyceridemia, elevated insulin, and insulin resistance in smoking patients was higher than those in nonsmoking patients, while overweight and hypertension were higher in the smoking controls than in nonsmoking controls (all P < .05). In smoking patients, triglyceridemia, high-density lipoprotein cholesterol, and fasting blood glucose were the main contributing components to MetS, while in nonsmoking patients, waist circumference, systolic blood pressure, triglyceridemia, high-density lipoprotein cholesterol, and fasting blood glucose were the main contributing components to MetS. In smoking patients, BMI and homeostatic model assessment for insulin resistance were associated factors of MetS (both P < .05). In nonsmoking patients, sex, BMI, insulin, and homeostatic model assessment for insulin resistance were associated factors of MetS (all P < .05). CONCLUSIONS: Our study indicates that smoking schizophrenia patients have a higher prevalence of MetS and metabolic disorders than nonsmoking patients. Moreover, smoking and nonsmoking patients have different contributing components and associated factors for MetS. Oxford University Press 2021-06-21 /pmc/articles/PMC8538889/ /pubmed/34153098 http://dx.doi.org/10.1093/ijnp/pyab038 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of CINP. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Regular Research Articles
Li, Zezhi
Wang, Shuning
Chen, Yuping
Wu, Xi
Gu, Yinjun
Lang, Xiaoe
Wu, Fengchun
Zhang, Xiang Yang
Smoking Affects the Patterns of Metabolic Disorders and Metabolic Syndrome in Patients With First-Episode Drug-Naive Schizophrenia: A Large Sample Study Based on the Chinese Han Population
title Smoking Affects the Patterns of Metabolic Disorders and Metabolic Syndrome in Patients With First-Episode Drug-Naive Schizophrenia: A Large Sample Study Based on the Chinese Han Population
title_full Smoking Affects the Patterns of Metabolic Disorders and Metabolic Syndrome in Patients With First-Episode Drug-Naive Schizophrenia: A Large Sample Study Based on the Chinese Han Population
title_fullStr Smoking Affects the Patterns of Metabolic Disorders and Metabolic Syndrome in Patients With First-Episode Drug-Naive Schizophrenia: A Large Sample Study Based on the Chinese Han Population
title_full_unstemmed Smoking Affects the Patterns of Metabolic Disorders and Metabolic Syndrome in Patients With First-Episode Drug-Naive Schizophrenia: A Large Sample Study Based on the Chinese Han Population
title_short Smoking Affects the Patterns of Metabolic Disorders and Metabolic Syndrome in Patients With First-Episode Drug-Naive Schizophrenia: A Large Sample Study Based on the Chinese Han Population
title_sort smoking affects the patterns of metabolic disorders and metabolic syndrome in patients with first-episode drug-naive schizophrenia: a large sample study based on the chinese han population
topic Regular Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538889/
https://www.ncbi.nlm.nih.gov/pubmed/34153098
http://dx.doi.org/10.1093/ijnp/pyab038
work_keys_str_mv AT lizezhi smokingaffectsthepatternsofmetabolicdisordersandmetabolicsyndromeinpatientswithfirstepisodedrugnaiveschizophreniaalargesamplestudybasedonthechinesehanpopulation
AT wangshuning smokingaffectsthepatternsofmetabolicdisordersandmetabolicsyndromeinpatientswithfirstepisodedrugnaiveschizophreniaalargesamplestudybasedonthechinesehanpopulation
AT chenyuping smokingaffectsthepatternsofmetabolicdisordersandmetabolicsyndromeinpatientswithfirstepisodedrugnaiveschizophreniaalargesamplestudybasedonthechinesehanpopulation
AT wuxi smokingaffectsthepatternsofmetabolicdisordersandmetabolicsyndromeinpatientswithfirstepisodedrugnaiveschizophreniaalargesamplestudybasedonthechinesehanpopulation
AT guyinjun smokingaffectsthepatternsofmetabolicdisordersandmetabolicsyndromeinpatientswithfirstepisodedrugnaiveschizophreniaalargesamplestudybasedonthechinesehanpopulation
AT langxiaoe smokingaffectsthepatternsofmetabolicdisordersandmetabolicsyndromeinpatientswithfirstepisodedrugnaiveschizophreniaalargesamplestudybasedonthechinesehanpopulation
AT wufengchun smokingaffectsthepatternsofmetabolicdisordersandmetabolicsyndromeinpatientswithfirstepisodedrugnaiveschizophreniaalargesamplestudybasedonthechinesehanpopulation
AT zhangxiangyang smokingaffectsthepatternsofmetabolicdisordersandmetabolicsyndromeinpatientswithfirstepisodedrugnaiveschizophreniaalargesamplestudybasedonthechinesehanpopulation